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Abstract: Despite the fact that cytopenia has been a common hematological entity seen in clinical practice for decades, 
the understanding of its etiopathogenesis has been changing, which in turn impacts on the management strategies. The 
current review focuses on the understanding of the current concepts and a brief overview of the management of aplastic 
anemia. As the spectrum of stem cell biology, etiology, and treatment from transplantation to graft-versus-host disease 
cannot be covered in few paragraphs, the most concise form is presented here.  
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INTRODUCTION 
Aplastic anemia is a syndrome, characterized by 
peripheral blood cytopenia and reduced marrow 
cellularity, resulting from various etiologies. Thus In 
contrast to conventional reasoning, where any 
peripheral cytopenia with marrow aplasia is considered 
as Aplastic Anemia, currently it is recommended to 
exclude similar disease entities such as MDS, PNH etc 
before concluding it is AA. This disease in majority of 
cases is acquired, though occasionally it may be 
congenital. In the presence of aplastic marrow, grading 
of the severity of the disease is based on absolute 
neutrophil count [ANC] [1]: 
1. Non severe AA (nSAA; PMN > 0.5 × 109/L) 
2. severe AA (SAA; PMN 0.2–0.5 × 109/L), and 
3. very severe AA (vSAA; PMN < 0.2 × 109/L).  
However, the above classification/ staging may no 
longer be relevant with current treatment strategies. 
PATHOGENESIS 
The etiopathogenesis is very complex and here we 
are presenting the two commonly accepted models. 
Soil, Seed and Fertilizer Hypothesis 
[1-3]- One of the old and widely accepted 
hypotheses relies predominantly on few observations. 
Laboratory evidence that suggests majority of cases of  
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idiopathic AA are due to immune suppression of the 
hematopoietic stem cell arose from observations of 
a) After BMT unexpected improvement of 
pancytopenia in some patients after allogeneic 
graft failure 
b) Successful BMT of identical twins generally 
requires some sort of immunosuppressive 
conditioning regimen. 
This further presumes that Normal hematopoiesis 
depends on a complex interaction of several cell types, 
including hemopoietic stem cells (HSC; the seed) and 
cells from the microenvironment (the soil), the T cells 
and growth factors [fertilizers]. 
STEM CELL DEFECT (SEED) 
Evidence for stem cells (seed) as targets came from 
the observations that:  
I. in vitro colony forming assays used to define the 
stem cell compartment showed that they were 
defective in cases 
II. two papers in 1996 showed profound deficits in 
the stem cell population in patients with AA 
III. at the time of clinical presentation the absolute 
number of stem cells is < 1% of normal 
population 
This is further augmented by the etiological agents 
that damage stem cells leading to AA like radiation, 
chemotherapy, Benzene and few drug metabolites. 
Soil and Fertilizer 
The concept of Stromal cell defect (soil) and Growth 
Factor defect (fertilizer) came from the observation that 
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A. Mononuclear cells from blood and marrow of AA 
patients suppress hematopoietic colony 
formation by normal marrow stem cells 
B. Laboratory studies have shown the stroma of AA 
patients is able to support normal stem cell 
growth and successful BMT implies intact stroma 
since it is not replaced in the transplant 
C. Stromal cells of AA patients tend to make 
increased levels of several growth factors (EPO, 
TPO, G-CSF) 
D. Selectively removing T cells from the sample, 
apparently improve in vitro colony formation 
E. Direct cellular cytotoxicity by T cells as 
evidenced by:  
a. blood and marrow of AA patients contain 
increased numbers of activated cytotoxic 
lymphocytes 
b. the numbers and activities of these cells 
decrease after ATG. 
F. And lastly the effect of Cytokines: 
a) T cells of AA patients overproduce both 
IFN-gamma and TNF-alpha 
b) both of these cytokines inhibit colony 
formation in vitro 
c) IFN-gamma induces nitric oxide synthase 
(NOS) and production of nitric oxide (NO) 
d) both induce expression of Fas receptor on 
CD34+ cells and activation of this receptor 
by its ligand induces apoptosis 
e) both appear to inhibit mitosis 
f)        IFN-gamma increases IFN regulatory 
factor 1 which inhibits transcription of 
cellular genes and entry into the cell cycle. 
This supports the etio-pathogenesis of the following 
agents drug metabolites, transfusion associated AA, 
post hepatitis associated and few idiopathic cases. 
While this explains the difficulty in deciding (1) 
which comes first and (2) whether there is a causal 
relationship between the two lead to the alternate 
hypothesis. 
ALTERNATE HYPOTHESIS [4] 
The hypothesis is very similar to filed cancerization 
effect, where a damage in the marrow such as genetic 
predesposition/toxins, leads to a trigger. This damaged 
stem cell may in turn trigger immune reaction to reject 
the “All the existing Marrow stem cell” resulting in 
Aplastic anemia, or may propogate in defective manner 
leading to Myelo Dysplatic Syndrome [ineffective 
meylo/erytropoeisis]. This therapy explains the 
PNH/MDS and AA together. This also explains high 
success rates of BMT as well as supports use of ATG 
in the conditioning regimens. 
DIAGNOSIS 
The work up includes a complete physical 
examination, and detailed history, peripheral blood 
examination, bone marrow aspiration, biopsy and flow 
cytometry with stress cytogeneitcs and FISH panel to 
rule out other causes. 
MANAGEMENT 
The target is to restore the normal counts, avoid 
long and short term side effects of drugs and 
cytopenia. Patients with moderate cytopenia, not 
requiring transfusions, can be offered outpatient 
treatment with anabolic steroids and cyclosporine 
(CsA), which were shown to be effective [5]. Patients 
with cytopenia requiring transfusions should be treated 
as in-patients, with either immunosuppressive therapy 
or bone marrow transplantation (BMT). It is important to 
understand that early treatment had long term better 
outcomes and the decision to start treatment should be 
as early as possible after confirmation of diagnosis. 
The choice between these two treatments is still 
debated and the discussion below will give an overview 
of the literature. 
SUPPORTIVE MEDICATIONS 
Growth Factors 
The literature does not support the use of G-CSF as 
an adjunt or alone in the management of AA. The 
potential advantages of using G-CSF for faster 
neutrophil recovery and the prediction to test for white 
blood cell (WBC) increments/ failures is not 
substantiated in log term trails [6-8]. Similarly Anemia 
does not respond to erythropoietin and their use is 
strongly discouraged. However multiple trials of 
thrombopoietin mimetics, eltrombopag, and romiplostim 
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are in progress, which in early phases are promising for 
platelet series [9]. 
Immunosuppressive Treatment 
Despite being a gold standard for ages, it is 
recommended only in a subset of patients in whom 
transplant is not an option. Treatment with 
antithymocyte globulin (ATG) yields superior survival 
when compared with supportive care alone. Horse ATG 
combined with cyclosporine remains standard as first-
line immunosuppressive therapy, based on a 
prospective randomized comparison with rabbit ATG 
and confirmed in several retrospective studies [10]. 
Although 66% responses are seen promptly after 
therapy, only 60% of such population shall be in true 
remission. Remaining patients eventually either relapse 
(defined by the need for renewed immune therapy) or 
blood counts are dependent on cyclosporine 
administration. Rabbit ATG at standard dosage is a 
more potent immunosuppressant than is horse ATG, 
but does not improve the rate of hematologic recovery 
in aplastic anemia. Other attempts to increase 
response rates by intensifying immunosuppression 
have failed, including the addition of high-dose 
corticosteroids, mycophenolate mofetil, or rapamycin. 
At present either horse or rabit ATG is considered 
standard.  
Cyclosporin 
A dose of 5 mg/kg orally per day for 6 months is 
considered as standard followed by taperin. Though 
various protocols are available, it is unclear exactly (1) 
when and (2) how fast this should be done. It is usually 
practiced and agreed that it is safe to start tapering 
CsA at 12 months of treatment (rather than 6 months) 
and tapering should be very slow (less than 10% of the 
dose/month) for at least 1 year, to minimize the risk of 
relapse. However it should be kept in mind that the risk 
of relapse is in the order of 30% and is not easily 
predicted [11, 12]. 
IST FOR SPECIAL POPULATION 
Pregnancy 
There is no data except for few case reports on how 
to manage AA in pregnancy. Hence the standard adult 
protocol are applied and it is always advisable to 
postpone therapy and consider supportive care only 
[transfusions]. Regarding second pregnancy, its is 
worth noting that it is possible but at the expense of a 
risk of relapse of the aplasia (approximately 20%) [13]. 
Elderly 
Although response rates and survival are lower 
compared with young patients, [projected 10 Yr survival 
of 45% for patients aged 51 to 70 years and 25% for 
patients over the age of 70 years], the current data 
suggest the use of the ATG, if there are no 
contraindications [14]. 
HEPATIC AND RENAL FAILURE PATIENTS 
There is no published literature in this group and the 
decision of treatment needs to be individualized. 
BONE MARROW TRANSPLANTATION [1, 10, 15] 
BMT is still the gold standard for newly diagnosed 
cases of AA, whenever feasible. With a success rate of 
over 90%, and EBMT/IBMTR study suggests that 
Periphearal Blood transplantations actually reduce 
survival compared with marrow transplantations, in 
patients with AA younger than 20 years, the first option 
should always be a bone marrow rather than peripheral 
blood stem cells. With standardized protocols of 
RIC/myeloablative regimens, and GVHD prophylaxis 
the outcomes are promising. 
HLA IDENTICAL BMT FOR PATIENTS OLDER THAN 
30 YEARS [15] 
The effect of age cannot be underestimated: overall 
survival in the last decade for HLA-identical sibling 
transplantations at 10 years is, respectively, 83%, 73%, 
68% and 51% for patients age ranges 1–20, 21–30, 
31–40 and ≥40 years; EBMT data). The age effect has 
remained significant over time, with survival in the 
range of 50% for patients over the age of 40 years. The 
EBMT is exploring the use of low-dose CY (300 mg/m2 
× 4) in combination with low-dose fludarabine (FLU; 30 
mg/m2 × 4) and ATG in patients older than 30 years: 
the initial results are encouraging, with transplantation 
mortality of 30%, rather than the expected 50%, but 
more patients need to be accrued (EBMT, unpublished 
data). Interestingly, a recent report has confirmed that 
the combination of FLU-CY and ATG may reduce the 
transplantation-related toxicity. 
UNRELATED DONOR TRANSPLANTS/ HALPO 
TRANSPLANTS [1, 10, 15] 
Significant progress has been made in the past few 
years, and at least three studies have addressed the 
issue of the conditioning regimen. The first of these 
studies tested de-escalating doses of radiation, those 
undergoing an unrelated donor (UD) transplantation 
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and various reduced intensity conditioning regimen 
which is very similar to the Japanese regimen: FLU-
CY-ATG and low-dose TBI (2 Gy) (unpublished). The 
overall data confirm that haemopoietic stem cells 
obtained from matched unrelated or haploidentical 
donors have a curative potential. 
CONCLUSIONS 
The practical approach in patients with Aplastic 
Anemia includes early institution of treatment in AA 
patients will improve overall outcomes and they require 
continuation of immunospression for minimum of 6 
months. Whenever possible transplant should be the 
first choice in these cases and in case of transplant 
ineligible patients, they should be offered to be entered 
into well-designed prospective clinical trials. 
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